None
Conditions
Interventions
The remimazolam combined with nalbuphine group (Group N):Slow intravenous injection of 0.1 mg/kg nalbuphine hydrochloride, followed by intravenous injection of 0.2 mg/kg remimazolam besylate
the remimazolam alone group (Group R):Slow intravenous infusion of 0.2 mg/kg of remimazolam succinate
the propofol alone group (Group P):Slow intravenous infusion of 1.5 mg/kg propofol and medium/long chain fat emulsion injection
Sponsors
Zhoushan Hospital
Eligibility
Sex/Gender
All
Age
60 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Written informed consent provided by the patient or their legal representative; 2. Normal mental and consciousness status before the procedure; 3. Meeting the indications for painless colonoscopy examination and voluntarily accepting anesthesia for the procedure; 4. Aged 60 to 70 years;
Exclusion criteria
Exclusion criteria: 1. Presence of severe organic diseases involving the heart, liver, lung, kidney, or other major organs; 2. Known allergy to any drug used in the study; 3. Long-term use of analgesic or sedative medications; 4. Cognitive impairment or inability to cooperate with the study procedures; 5. Refusal or inability to provide informed consent;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence rate of vagus nerve reflexes; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemodynamic indicators: including heart rate, mean arterial pressure, systolic blood pressure and diastolic blood pressure;Effectiveness indicators: include the onset time of sedation and the recovery time from anesthesia.;Safety indicators: Incidence of adverse reactions during the perioperative period; | — |
Countries
China
Contacts
Public ContactBo Liu
Zhoushan Hospital
Outcome results
None listed